[HTML][HTML] The current understanding of KRAS protein structure and dynamics
T Pantsar - Computational and structural biotechnology journal, 2020 - Elsevier
One of the most common drivers in human cancer is the mutant KRAS protein. Not so long
ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however …
ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however …
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
M Nagasaka, Y Li, A Sukari, SHI Ou, MN Al-Hallak… - Cancer treatment …, 2020 - Elsevier
Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are among the most
common aberrations in cancer, including non-small cell lung cancer (NSCLC). The lack of …
common aberrations in cancer, including non-small cell lung cancer (NSCLC). The lack of …
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
A Mohanty, A Nam, S Srivastava, J Jones… - Science …, 2023 - science.org
Inherent or acquired resistance to sotorasib poses a substantialt challenge for NSCLC
treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells …
treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells …
Decrypting Allostery in Membrane-Bound K-Ras4B Using Complementary In Silico Approaches Based on Unbiased Molecular Dynamics Simulations
M Castelli, F Marchetti, S Osuna… - Journal of the …, 2023 - ACS Publications
Protein functions are dynamically regulated by allostery, which enables conformational
communication even between faraway residues, and expresses itself in many forms, akin to …
communication even between faraway residues, and expresses itself in many forms, akin to …
Intrinsically disordered proteins play diverse roles in cell signaling
Signaling pathways allow cells to detect and respond to a wide variety of chemical (eg Ca2+
or chemokine proteins) and physical stimuli (eg, sheer stress, light). Together, these …
or chemokine proteins) and physical stimuli (eg, sheer stress, light). Together, these …
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …
[HTML][HTML] Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Novel inhibitors targeting Kirsten rat sarcoma virus homolog (KRAS) KRAS G12C in various
cancers have shown good initial efficacy, but therapy-related drug resistance eventually …
cancers have shown good initial efficacy, but therapy-related drug resistance eventually …
Therapeutics targeting mutant KRAS
KZ Thein, AB Biter, DS Hong - Annual review of medicine, 2021 - annualreviews.org
Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of …
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of …
Oncogenic Ras isoforms signaling specificity at the membrane
R Nussinov, CJ Tsai, H Jang - Cancer research, 2018 - AACR
How do Ras isoforms attain oncogenic specificity at the membrane? Oncogenic KRas,
HRas, and NRas (K-Ras, H-Ras, and N-Ras) differentially populate distinct cancers. How …
HRas, and NRas (K-Ras, H-Ras, and N-Ras) differentially populate distinct cancers. How …
Phenotypic plasticity, bet-hedging, and androgen independence in prostate cancer: role of non-genetic heterogeneity
MK Jolly, P Kulkarni, K Weninger, J Orban… - Frontiers in …, 2018 - frontiersin.org
It is well known that genetic mutations can drive drug resistance and lead to tumor relapse.
Here, we focus on alternate mechanisms—those without mutations, such as phenotypic …
Here, we focus on alternate mechanisms—those without mutations, such as phenotypic …